Researchers reported preclinical progress on engineered immune cell engagers (ICEs) designed to better coordinate activating and inhibitory signals within macrophages for solid tumor clearance. In work published in Nature Biotechnology, the team describes a logic-gated cis-targeting strategy aimed at overcoming limited ICE efficacy in solid tumors. The approach is built to coordinate immune response signals within the same macrophage population, which the authors say can improve tumor clearance in mouse models. The findings add another design pattern to the ICE field that increasingly emphasizes signal logic and cell-type-specific coordination rather than single-pathway targeting. For drug developers, the report reinforces how next-generation immunotherapies are evolving toward multi-signal control architectures—potentially improving therapeutic index in solid tumors.